FY2019 Earnings Forecast for Marinus Pharmaceuticals Inc Issued By Cantor Fitzgerald (NASDAQ:MRNS)
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) – Equities researchers at Cantor Fitzgerald issued their FY2019 earnings estimates for Marinus Pharmaceuticals in a research note issued to investors on Thursday, October 17th. Cantor Fitzgerald analyst A. Young anticipates that the biopharmaceutical company will earn ($0.99) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 target price on the stock. Cantor Fitzgerald also issued estimates for Marinus Pharmaceuticals’ FY2020 earnings at ($0.97) EPS.
A number of other brokerages have also recently weighed in on MRNS. Zacks Investment Research cut Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 10th. LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $5.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, September 26th. ValuEngine upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 7th. HC Wainwright set a $5.00 target price on Marinus Pharmaceuticals and gave the company a “buy” rating in a report on Friday. Finally, Mizuho reduced their target price on Marinus Pharmaceuticals from $5.00 to $1.70 and set a “neutral” rating on the stock in a report on Tuesday, July 23rd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $8.68.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.01).
A number of institutional investors have recently modified their holdings of the stock. D. E. Shaw & Co. Inc. acquired a new position in shares of Marinus Pharmaceuticals during the second quarter worth about $76,000. Wells Fargo & Company MN lifted its stake in shares of Marinus Pharmaceuticals by 199.6% during the second quarter. Wells Fargo & Company MN now owns 52,642 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 35,072 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Marinus Pharmaceuticals by 32.7% during the second quarter. Charles Schwab Investment Management Inc. now owns 126,761 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 31,260 shares in the last quarter. Morgan Stanley lifted its stake in shares of Marinus Pharmaceuticals by 1,679.6% during the second quarter. Morgan Stanley now owns 187,889 shares of the biopharmaceutical company’s stock worth $780,000 after purchasing an additional 177,331 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Marinus Pharmaceuticals by 1.9% during the second quarter. Northern Trust Corp now owns 548,467 shares of the biopharmaceutical company’s stock worth $2,276,000 after purchasing an additional 10,204 shares in the last quarter. Hedge funds and other institutional investors own 64.13% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Featured Article: What are momentum indicators and what do they show?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.